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Abstract 
Aim: Intranasal aerosol administration of drugs is widely used by ENT specialists. Although 
clinical evidence is still lacking, intranasal nebulization appears to be a promising therapeutic 
option for local drug delivery, targeting anatomic sites beyond the nasal valve. The sonic 
nebulizer NL11SN associates a 100 Hertz (Hz) sound to the aerosolization to improve 
deposition in the nasal/paranasal sinuses. The aim of the present study was 1) to evaluate in 
vivo the influence of associating a 100Hz sound on sinus ventilation and nasal and pulmonary 
aerosol deposition in normal volunteers, and 2) to quantify in vitro aerosol deposition in the 
maxillary sinuses in a plastinated head model. 
Material and methods: Scintigraphic analysis of 81mKr gas ventilation and of sonic aerosol 
(99mTc-DTPA) deposition using the NL11SN was performed in vivo in 7 healthy volunteers. 
In parallel, NL11SN gentamicin nebulization was performed, with or without associated 
100Hz sound, in a plastinated human head model; the gross amount of gentamicin delivered 
to the paranasal sinuses was determined by fluorescence polarization immunoassay. 
Results: Associating the 100Hz sound to 81mKr gas ensured paranasal sinus ventilation in 
healthy volunteers. 99mTc-DTPA particles nebulized with the NL11SN were deposited 
predominantly in the nasal cavities (2/3, vs. 1/3 in the lungs). In vitro, the use of NL11SN in 
sonic mode increased gentamicin deposition threefold in the plastinated model sinuses 
(p<0.002); the resulting antibiotic deposit would be sufficient to induce a local therapeutic 
effect. 
Conclusion: The NL11SN nebulizer ensured preferential nasal cavity aerosol deposition and 
successfully targeted the maxillary sinuses. 
 
Keywords: sonic aerosol; 100 Hertz; scintigraphy; healthy volunteers; plastinated head model; 
nasal; sinus; rhinosinusitis. 
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1. Introduction 
 
Although the efficacy of nebulizing pulmonary antibiotics and corticosteroids has been 
demonstrated in many studies [1,2], nebulization of antibiotics with a nasal target remains 
controversial [3,4]. The French health products safety agency AFSSAPS does not recognize 
an indication for local antibiotics in rhinosinus pathology [5]. In theory, however, 
nebulization has the advantage over classic administration routes of delivering the drug 
directly to the target organ, thereby avoiding systemic side-effects while increasing the local 
dose. Consequently, despite a relative lack of clinical evidence and the small number of 
published studies, nasal nebulization is in fact frequently used in ENT and by family doctors 
[6,7]. Nasal aerosol therapy is used in most acute and chronic nasal cavity and sinus 
pathologies, enabling direct application to the rhinosinusal mucosa, with a rapid clinical 
response and minimal side-effects. It is particularly used in failure of reference per os or spray 
treatment [6,8]. Nebulization may indeed be an interesting treatment option in nasal 
antibiotherapy [9,10]. 
There are currently no nasal antibiotic sprays; sprays, moreover, fail to target potentially 
infected anatomic sites such as the maxillary sinus, ethmoid cells or middle turbinate [11,12]. 
As nebulizers produce finer particles than sprays (4µm vs. 30µm), they can target anatomic 
areas beyond the nasal valve, but still fail to reach the maxillary sinuses. Associating a 100Hz 
acoustic wave, however, enhances ventilation [13] and aerosol deposition [14] in the 
sinonasal cavities. Nasal sonic nebulizers would thus seem to generate the best adapted 
aerosols for local treatment of rhinosinusitis.  
 
The present study sought to quantify respiratory pathway and maxillary sinus deposition of 
the aerosol produced by a nasal sonic nebulizer, NL11SN (DTF, Saint Etienne, France) 
designed to optimize nasal cavity and maxillary sinus deposition by associating a 100 Hz 
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sound to the aerosol [15]. Results with the system are reported (i) in vivo in healthy 
volunteers, using a radioactive tracer, and (ii) in vitro with gentamicin in a plastinated human 
head model.  
 
2. Material and Methods  
 
2.1. Nasal sonic nebulizer 
 
Nebulization used an ATOMISOR NL11SN (NL11SN) nasal sonic nebulizer with an 
ATOMISOR AOHBOX® compressor (DTF Médical, Saint-Etienne, France). The aerosol 
was administered via flexible C28E nasal plugs (DTF Médical, Saint-Etienne, France). 
 
2.2. Healthy volunteer scintigraphy study.  
 
 2.2.1. Study population  
This single-center study included 7 healthy male, non-smoking volunteers aged 21 to 36 
years, with a mean height of 181 ± 3 cm and mean weight 77 ± 10 kg.  
The study design was approved by the ethics committee of the Saint Luc University Clinics of 
the Catholic University of Leuven (UCL, Belgium), where the study was performed. In line 
with the Declaration of Helsinki and good clinical practice guidelines, the healthy volunteers 
signed their written informed consent before final inclusion.  
The subjects were judged healthy at the first selection consultation after a complete medical 
check-up comprising physical examination, vital signs assessment, medical and surgical 
history and inclusion/exclusion criteria: the pulmonary scintigraphy examination required 
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subjects to be equivalent in sex, age, height and weight so as to limit and harmonize thoracic 
tissue attenuation within the study population.     
The main grounds for exclusion were history of cardiovascular pathology, allergy, asthma or 
other pulmonary pathology or any ENT, and especially rhinosinusal, pathology (polyposis or 
any type of rhinosinusitis) or ENT or head and neck surgery (whether repair or functional).  
The clinical examination was completed by nasal cavity rhinoscopy; subject 3 showed right 
nasal deviation and subject 5 a right septal spur, but these were considered to be anatomic 
variants not entailing exclusion. 
 
 2.2.2. Scintigraphic ventilation study of the contribution of a 100 Hz sound 
Krypton 81m (81mKr) ventilation was performed to study the effect on maxillary sinus 
penetration of associating a 100 Hz sound and to determine the anatomic upper airway and 
lung regions. 81mKr gas (81Rb/81mKr generator, Covidien, Petten, Netherlands) was 
continuously administered via nasal plugs to achieve upper and lower airway ventilation.  
The following 2-min scintigraphic acquisitions were performed using a STARPORT 400 
AC/T gamma camera (General Electric, Horsholm, Denmark):  
• Gas-1: nasal cavities on right lateral head view; 
• Gas-2: nasal cavities on AP head view on ventilation without sound; 
• Gas-3: nasal cavities on AP head view on ventilation with 100 Hz sound; 
• Gas-4: lungs on posterior thorax view. 
 
 2.2.3. Sonic 99mTc-DTPA aerosol deposition study 
The NL11SN nebulizer was loaded with a 3 ml solution containing 25mg DTPA (Diethylene-
Triamine Penta-Acetic Acid) with 74 MBq Technetium 99m (99mTc) tracer (TechneScan 
DTPA, Mallinckrodt Medical, Petten, Netherlands).  
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Ahead of the aerosol session, subjects were trained to inhale the aerosol by the nose and 
breathe out by the mouth. An absolute filter system (BB50TE, Pall Medical, France) protected 
the ambient air and quantified exhaled aerosol activity. Nebulization was associated to a 100 
Hz sound for 10 minutes.  
Immediately after inhalation, the subject sat face to the camera for 3 acquisitions: 
• Aerosol-1: nasal cavities on right lateral head view;  
• Aerosol-2: thorax on posterior view; 
• Aerosol-3: residual nebulizer and accessory activity.  
 
 2.2.4 Image processing 
Total deposited airway activity was calculated on the activity-balance method, consisting in 
subtracting non-deposited activity from the activity initially introduced in the nebulizer. 
Results were corrected for background noise and radioactive decay.  
Regions were traced around the anatomic areas of interest (nasal cavities, lungs, stomach) 
from the ventilation images and applied to each deposition image. Percentage aerosol 
deposition per region of interest was calculated from the total deposited activity. Deposited 
DTPA mass (µg) was also determined for each region from the DTPA mass initially 
introduced in the nebulizer. 
 
2.3. In vitro gentamicin sonic aerosol deposition study 
Intrasinus concentrations of an antibiotic, gentamicin, nebulized with and without associated 
100 Hz sound, were compared in a plastinated head anatomic model.  
2.3.1. Plastinated head anatomic model 
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The human head plastination technique developed and adapted for ENT modeling in the 
anatomy laboratory of the Saint-Etienne Medical School (France) was used to create several 
plastinated specimens, three of which were dedicated to functional sinonasal cavity studies 
[16,17].  
The plastinated anatomic specimens were obtained following the usual stages of this 
technique: specimen preparation (3 days), formaldehyde fixation (3 months), dehydration and 
degreasing with acetone (1-2 months), silicone impregnation (10-20 days), and 
polymerization (2-3 months). The polymerization was optimized to avoid tissue retraction 
[17]. The plastinated heads were validated as aerosol deposition models after anatomic, 
geometric and aerodynamic analysis, using classical clinical techniques: rhinoscopy, 
endoscopy, CT, rhinomanometry and acoustic rhinometry. 
The models' maxillary sinuses were opened using a sagittal cut involving the lateral sinus 
wall. Two movable plexiglass plates were used to close the sinuses hermetically during 
nebulization (Figure 1). This gave access to the sinus antrum to collect the deposited aerosol.  
 
 2.3.2. Gentamicin nebulization 
Gentamicin (Gentallin®, Schering-Plough SAS, Courbevoie, France), an aminoglycoside 
active on Gram-negative bacteria and staphylococci, with recognized efficacy on the bacteria 
implicated in rhinosinusitis [18,19], was chosen as marker for its solidity and specific 
deposition on routine methods. Two concentrations were used: 40 and 80 mg/ml.   
 
The NL11SN nebulizer was loaded with 4 ml gentamicin and connected to the model nostrils 
via nasal plugs (Figure 1).  
Nebulization lasted 10 minutes. The plexiglass plates were then withdrawn and the maxillary 
sinuses were given 4 rinses of 1 ml physiological saline by syringe to collect the gentamicin 
 8
deposited on the sinus walls. The rinse liquid was kept at -20°C for subsequent measurement 
of the collected gentamicin. 
After each nebulization, the specimen was liberally washed and dried in free air for at least 48 
hours. 
   
Nebulization (n= 112) was performed either in sonic mode (with 100 Hz sound) or classical 
mode (without sound). Physiological saline nebulization (n=34) was used to check wash-out: 
i.e., that no gentamicin remained in the sinuses.  
 
 2.3.3. Gentamicin assay 
Gentamicin was assayed on 291 sinus rinse liquid samples by immuno-enzymatic analysis 
(fluorescence polarization immunoassay) on a TDX/FLX® device (Abbott Diagnostics, 
Rungis, France). Assays were performed in triplicate using Gentamicin® reagents (Abbott 
Laboratories, Diagnostic Division, EU) with sensitivity of 0.27mg/L.   
 
2.4. Statistical analysis 
The impact of a 100 Hz sound on gentamicin sinus deposition in the plastinated head model 
was assessed by t test (XLSTATS®). The significance threshold was set at p<0.05. 
 
3. Results 
The in vivo inhalation sessions (81mKr ventilation and 99mTc-DTPA nebulization) were well 
tolerated by all subjects, and there were no adverse events. The upper and lower airways 
could be visualized with the 81mK gas in all cases. The recorded images testified to a positive 
impact on maxillary sinus penetration of associating the 100 Hz sound to ventilation (Figure 
2, Gas-2 and Gas-3).  
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The images also enabled anatomic regions to be defined in the upper airways and lungs, so as 
to quantify sonic aerosol deposition of nasally inhaled 99mTcDTPA (Figure 1, Aerosol-1).  
In terms of 99mTc-DTPA mass, respiratory pathway aerosol distribution was 2,400 ± 475 µg in 
the upper airways (nasal cavities and rhinopharynx) and 925 ± 425 µg in the lungs, 
demonstrating effective targeting of the nasal cavities (two-thirds of the activity) as compared 
to the lungs. These upper airway calculations took account of swallowing and nasal clearance 
(Table 1).  
The images, however, showed only a small amount of aerosol in the maxillary sinuses, far 
less than the krypton seen to penetrate them under ventilation scintigraphy. Valid image 
processing to quantify maxillary region aerosol deposition precisely was not feasible due to 
the difficulty of situating the regions anatomically. 
Little radioactive DTPA (0 ± 25 µg) was found in the stomach, indicating that little aerosol 
was swallowed during the nebulization session.  
 
In vitro, the 112 gentamicin nebulizations and iterative rinsing did not affect the plastinated 
head anatomy. Absence of gentamicin in the sinuses was checked by assaying the sinusal 
liquid collected after physiological saline (result: < 0.27mg/l).  
The results detailed in Table 2 show an up to 3-fold increase (p<0.05) in gentamicin 
concentration in the maxillary sinuses when the 100 Hz sound was associated to nebulization, 
for both types of concentration tested. Deposition was significantly greater in the left than the 
right sinus, with or without associated sound (p<0.05).  
 
4. Discussion  
The interest of associating a 100 Hz sound to nasal administration was studied first directly in 
healthy volunteers by in vivo 81mKr ventilation scintigraphy. The gas was delivered nasally by 
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an NL11SN nebulizer, and nasal cavity ventilation was recorded laterally before and during 
the addition of sound. The images (Figure 2, Gas-2 and Gas-3) display the impact of 
associated 100 Hz sound on maxillary sinus penetration, enhancing ventilation with increased 
gas exchange between nasal cavities and maxillary sinuses. 
A drug aerosol, however, may show different aerodynamic behavior from a gas, with 
consequently varying impact of 100 Hz acoustic vibrations. The airway distribution of the 
nasally inhaled sonic aerosol was therefore studied using 99mTc-DTPA as radioactive tracer. 
The mass of 99mTc-DTPA deposited in the upper airways and lungs was calculated for 
anatomic regions defined on the ventilation images. Two-thirds of the sonic 99mTc-DTPA 
aerosol was distributed in the upper airways, and one-third in the lungs. Within the nasal 
cavities, aerosol deposition stretched from the nasal vestibule to the pharynx (Figure 2, 
Aerosol-1), rather than being restricted to the first centimeters of the nasal fossae as usually 
described in the literature [11], which implies that it passed through the middle and inferior 
nasal meati.  
This in vivo study, however, involved limitations, one methodological and the other related to 
the use of healthy subjects. The methodology provided only overall quantification of upper 
airway deposition, without detailed differentiation of deposition in therapeutic target sites 
such as the maxillary sinuses. The proximity of the maxillary sinuses to the nasal fossae 
makes precise localization within the upper airways as a whole difficult [17,20], especially 
due to the Compton Effect. This means that the theoretic treatment efficacy of target 
deposition cannot be assessed. Moreover, the healthy volunteers themselves represented a 
limitation to the study of the targeting of areas of therapeutic interest, as their maxillary ostia 
were open (as seen on 81mKr ventilation) unlike in the general case of patients with rhinologic 
pathology: patients likely to be concerned by nasal antibiotherapy for chronic rhinosinusitis 
will generally have a closed ostium [21].  
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The second, in vitro, study examined the effect of associating a 100 Hz sound to a gentamicin 
aerosol in a plastinated human head model. Plastination provided a model conserving the 
mucosa, anatomy and aerodynamics of the nasal cavities and sinuses. Moreover, the active 
substances nebulized and deposited in the maxillary sinuses could be assayed in situ.       
The results demonstrated that the gentamicin nebulized by the NL11SN penetrated and was 
deposited in the model's maxillary sinuses. The main factor affecting sinusal deposition was 
the 100 Hz sound, in presence of which the gentamicin concentration collected from the 
sinuses was significantly increased, by a factor of 1.6 to 3 (Table 2). For a given gentamicin 
dose, the increase in sinus deposition was equivalent in the 2 sinuses, although the absolute 
amount of deposit was significantly different between the two (p<0.05), probably due to 
geometrical differences between the left and right maxillary sinus ostia. Rhinomanometric 
measurements taken on the same model showed greater right than left ostium resistance 
[17,22]. The gain in maxillary gentamicin deposition provided by the associated sound was 
independent of ostium geometry.  
Although the model enabled sinus deposits to be collected, it involved certain limitations. The 
gentamicin assay results were highly variable, due to the technical difficulty of rinsing the 
sinuses with physiological saline to collect the gentamicin. However well controlled the 
technique, sinus antrum anatomy and the uneven aerosol deposition over the cavities meant 
that collection was neither exhaustive nor strictly reproducible from one trial to another. 
Moreover, sinus rinsing was suboptimal, as it included neither the lateral wall of the maxillary 
sinus nor any possible physical gentamicin absorption by the plastinated sinus mucosa; the 
real quantity of deposited gentamicin in the sinuses was therefore once again inevitably 
underestimated. 
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There was further a technical limitation inasmuch as the plastinated head specimen was not 
ventilated and thus was "passive" under aerosol administration. Inhalation and exhalation of 
the aerosolized particles was not reproduced, which may have affected the deposition kinetics 
as compared to a ventilated model. This lack of "respiration" might reduce or on the contrary 
increase sinus penetration: the former, as airflow through the nasal cavities under inspiration 
(acceleration) and expiration (vortex) maintains sinus aeration, enabling gas exchange with 
the nasal cavities (sinus respiration) [21,22,]; or the latter, due to aerosol accumulation in the 
nasal fossae, increasing penetration into the maxillary sinuses via the ostia. 
 
Nasal antibiotic nebulization is especially controversial due to a lack of data as to the quantity 
of active molecules actually deposited, their potential clinical efficacy and the expected 
therapeutic doses.  
The present in vivo results in healthy subjects and in vitro results in the plastinated model 
showed the NL11SN sonic nebulizer to be suitable for targeting the upper airways, including 
the sinus cavities. 
The plastinated head model could be useful for initial assessment of the theoretic efficacy of 
an antibiotic deposit in the maxillary sinuses according to the quantities of active substance 
collected. In the present study, a mean 1.35 mg/L and 2.33 mg/L were measured in the rinse 
liquid from the right and left sinuses respectively, corresponding to a mean mass of 3.31 µg 
collected from the sinuses.  
In terms of deposition efficacy, it is possible to estimate whether the quantity of deposited 
gentamicin was sufficient to ensure a local therapeutic effect. Sinus gentamicin deposition can 
be compared to the recognized effective pulmonary deposition of a reference aminoglycoside 
by normalizing deposition per unit tissue area. Among the aminosides used in nebulization, 
tobramycin (TOBI®) shows recognized efficacy in Pseudomonas aeruginosa pulmonary 
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infection in mucoviscidosis patients. In vivo studies reported about 45 mg tobramycin 
deposited in the lungs using the reference pneumatic nebulizer [1].  
From these data, the tobramycin deposition rate in the lungs can be estimated at 0.0346 
µg/cm2 (for a maximum deposition area of 130 m2). 
If the maxillary sinus is assimilated to a sphere of about 17 cm3 (mean = 15 to 20 cm3 in the 
literature) [23,24,25], the potential aerosol deposition area in a sinus will be 31.93 cm2. 
Gentamicin deposition in the plastinated head sinuses was estimated at 0.05183 µg/cm2.   
According to these new data, the quantity of gentamicin deposition in the in vitro model 
sinuses can be estimated as being 1.5 fold greater (0.05183 µg/cm2 vs. 0.0346 µg/cm2) than 
the reference aminoside deposition in the lungs. Thus, on this initial approach, the quantity of 
gentamicin collected from the maxillary sinuses would seem to be sufficient to induce a local 
anti-infection effect. These results should be confirmed in a clinical assessment of the 
therapeutic efficacy of antibiotic deposition by nasal sonic aerosol. 
 
5. Conclusions 
The present study showed that sonic nebulization (i.e., nebulization coupled to a 100 Hz 
sound), as implemented using the NL11SN nebulizer, optimized aerosol deposition in the 
nasal cavities (two-thirds of activity) and effectively targeted anatomic regions of interest 
such as the maxillary sinuses. Maxillary sinus penetration proves passage through the middle 
meatus, the center of sinus pathology. Thus the nasal sonic aerosols produced by the NL11SN 
can treat certain rhinosinus pathologies.  
By comparison with the results for pulmonary deposition normalized per unit of tissue area, 
the amount of sinus drug deposition seems sufficient to induce a local anti-infection effect. 
The plastinated human head seems to be a useful model for therapeutic assessment of the 
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theoretic efficacy of sinus deposition of drugs, and of antibiotics in particular. The results 
show that rhinologic antibiotic nebulization may be useful, avoiding acquisition of resistance. 
Clinical studies will be required to validate the treatment efficacy of nebulized deposition of 
antibiotics or other molecules using the NL11SN sonic nebulizer in various rhinosinus 
pathologies (infectious and/or inflammatory), so as to determine clinical applications. 
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Figures 
 
 
Figure 1: Nebulization of gentamicin in a plastinated head model, using the ATOMISOR 
NL11SN nasal sonic nebulizer connected to an ATOMISOR AOHBOX® compressor.  
The pressure input tube ensured continuous compressed air inflow and the sound input tube 
ensured conduction of the 100 Hz sound produced by the compressor. The sonic nebulizer 
was connected to the plastinated head nostrils via nasal plugs. The two movable plexiglass 
plates on either side of the model hermetically closed external access to the maxillary sinuses.  
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Figure 2: Scintigraphy images in healthy volunteers, using the NL11SN sonic nebulizer and 
ATOMISOR AOHBOX® compressor: 
Aerosol-1: 99mTc-DTPA aerosol deposition with associated 100 Hz sound (right lateral nasal 
cavity view); 
Gas-2: 81mKr ventilation without associated sound (anterior side of the nasal cavities); 
Gas-3: 81mKr ventilation with associated 100 Hz sound (anterior side of the nasal cavities). 
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Table 1: 99mTc-DTPA aerosol deposit (µg) from NL11SN nebulizer/AOHBOX® compressor, 
in 7 healthy subjects (mean ± SD). 
 
Upper airwaysa  2,400 ± 475  
Lungs  925 ± 425  
Stomach  0 ± 25 
a
 Upper airways taking account of nasal cavities, rhinopharynx and stomach. 
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Table 2: Mean gentamicin concentration (mg/l) collected from the left and right maxillary 
sinuses of the plastinated head model after classic nebulization (without associated sound) and 
sonic nebulization (with associated 100 Hz sound) for 2 antibiotic formulae (40mg/ml and 
80mg/ml), using the NL11SN nebulizer/AOHBOX® compressor. 
 
Loaded gentamicin 
concentration 
(mg/ml) 
Type of 
nebulization 
Gentamicin concentration collected in 
maxillary sinuses (mg/l) 
 
Right sinus  Left sinus  
40 classic < 0.27a < 0.27 p = 0.679 ** 
40 sonic 0.64 ± 0.22 0.73 ± 0.32 p = 0.242 ** 
     p = 0.002 *  p = 0.005 *  
80 classic 0.63 ± 0.52 1.19 ± 1.03 p = 0.005 ** 
80 sonic 1.35 ± 0.91 2.33 ± 1.49 p = 0.019 ** 
   p <0.0001 * p <0.0001*  
a
 mean concentration below assay kit sensitivity threshold (0.27mg/L)  
* t test,  classic vs. sonic nebulization 
** t  test, right vs. left sinus  
 
